Table 2.

Levels of Telomerase Activity in HD-Affected Lymph Nodes, Non-Hodgkin's Lymphomas, Reactive Lymph Nodes, and in Permanent Cell Lines

Sample Telomerase Activity*No.
Mean Median Range
HD, all cases 0.58 0.54  0-2.50  27  
 Nodular sclerosis  0.65  0.50 0-2.50  13  
 Mixed cellularity  0.47  0.52  0-0.74 9  
 Lymphocytic predominance  0.72  0.60  0.52-1.15 4  
Non-Hodgkin's lymphoma, all cases  1.81  1.87 0.58-3.66  9  
 High-grade malignant  2.80  2.60 2.28-3.66  4  
 Low-grade malignant  1.04  0.92 0.58-1.87  5  
Reactive lymph node  0.30  0.19 0-1.10  15  
Cell lines  
 HDLM-2 (HD-derived)  3.98 
 KM-H2 (HD-derived)  7.87  
 L-428 (HD-derived)  8.17 
 1301 (T cell lymphoblastic)  17.25  
 T47D1 (breast carcinoma)  1.37  
 Hela (cervical carcinoma)  2.95    
Sample Telomerase Activity*No.
Mean Median Range
HD, all cases 0.58 0.54  0-2.50  27  
 Nodular sclerosis  0.65  0.50 0-2.50  13  
 Mixed cellularity  0.47  0.52  0-0.74 9  
 Lymphocytic predominance  0.72  0.60  0.52-1.15 4  
Non-Hodgkin's lymphoma, all cases  1.81  1.87 0.58-3.66  9  
 High-grade malignant  2.80  2.60 2.28-3.66  4  
 Low-grade malignant  1.04  0.92 0.58-1.87  5  
Reactive lymph node  0.30  0.19 0-1.10  15  
Cell lines  
 HDLM-2 (HD-derived)  3.98 
 KM-H2 (HD-derived)  7.87  
 L-428 (HD-derived)  8.17 
 1301 (T cell lymphoblastic)  17.25  
 T47D1 (breast carcinoma)  1.37  
 Hela (cervical carcinoma)  2.95    

*The level of telomerase activity was analyzed in extracts at 0.28 μg/assay without RNase protection using the TRAP assay and ITAS (see the Materials and Methods). The telomerase activity levels in HD were significantly increased compared with reactive lymph nodes (P = .05) and significantly decreased compared with non-Hodgkin's lymphomas (P = .001).

One case could not be subclassified.

Close Modal

or Create an Account

Close Modal
Close Modal